Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

Share Price is delayed by 15 minutes
Get Live Data
43.80    0.00 (0.00%)
Bid:
42.80
Ask:
44.80
Spread: 2.00 (4.673%)
Market Cap: £68.37m
MIG3 Live PriceLast checked at - London Stock Exchange

Intraday Maven Grwth 3 Share Chart

Unaudited NAV and Second Interim Dividend

4 Dec 2025 10:35

RNS Number : 2835K
Maven Income and Growth VCT 3 PLC
04 December 2025
 

Maven Income and Growth VCT 3 PLC

 

Unaudited Net Asset Value (NAV) and Second Interim Dividend

 

Unaudited NAV

The Directors of Maven Income and Growth VCT 3 PLC (the Company) confirm:

 

· Unaudited net asset value (NAV)1 of 47.91p per Ordinary Share as at 30 November 2025, compared to 46.50p per Ordinary Share as at 31 August 2025; and

 

· NAV total return2 of 152.78p per Ordinary Share as at 30 November 2025, compared to 151.37p per Ordinary Share as at 31 August 2025.

 

Dividends

The Directors understand the importance of tax free distributions to Shareholders and, as announced in the 2024 Annual Report, enhanced the dividend policy by increasing the target annual yield from 5% to 6% of NAV per Ordinary Share at the immediately preceding year end. Shareholders should be aware that this remains a target and that decisions on distributions take into consideration a number of factors, including the realisation of capital gains, the adequacy of distributable reserves, the availability of surplus revenue and the VCT qualifying level, all of which are kept under close and regular review. As the portfolio continues to expand and the proportion of younger, growth companies increase, the timing of distributions will be more closely linked to realisation activity, whilst also reflecting the requirement to maintain the VCT qualifying level.

 

First Interim Dividend

Following the profitable realisation of Horizon Ceremonies in July 2025, an enhanced interim dividend in respect of the year ended 30 November 2025, of 2.00 pence per Ordinary Share, was paid on 29 August 2025.

 

Second Interim Dividend

In line with the new policy, and following the recent realisation of the investment in Ensco 969 Limited, trading as DPP, the Board is pleased to declare that a second interim dividend in respect of the year ended 30 November 2025, of 1.00p per Ordinary Share, will be paid on 16 January 2026 to Shareholders on the register at close of business on 12 December 2025. Since the Company's launch, and after receipt of this second interim dividend, 105.87p per Ordinary Share will have been distributed in tax free dividends. It should be noted that the effect of paying dividends is to reduce the NAV of the Company by the total cost of the distribution. 

 

Dividend Investment Scheme (DIS)

The Company has in place a DIS, through which Shareholders may elect to have their dividend payments used to subscribe for new Ordinary Shares issued by the Company under the standing authority granted by Shareholders at Annual General Meetings. Shares issued under the DIS should qualify for VCT tax relief applicable for the tax year in which they are allotted, subject to an individual Shareholder's particular circumstances. 

 

Shareholders can elect to participate in the DIS in respect of future dividends, including this second interim dividend, due to be paid on 16 January 2026, by completing a DIS mandate, which must be received by the Registrar (The City Partnership) by 2 January 2026, this being the next dividend election date. The mandate form, terms & conditions and full details of the scheme (including tax considerations) are available from the Company's webpage at: www.mavencp.com/migvct3. Election to participate in the DIS can also be made through the Registrar's online investor hub at: https://maven-cp.cityhub.uk.com/login.

 

Further to the information disclosed above, the Directors confirm that they are satisfied that all inside information (as defined by Article 7 of the Market Abuse Regulation (596/2014/EU)) that the Directors and the Company may have in their possession relating to the Company during the 30 day closed period leading up to the announcement of its annual results for the year ended 30 November 2025 has been or will be notified to a regulatory information service.

 

Notes:

1The NAV as at 30 November 2025 is unaudited and reflects the closing bid price of quoted securities as at that date. The NAV incorporates the Directors' valuation of unlisted investments as at 30 November 2025.

 

2NAV total return is the sum of NAV per Ordinary Share and dividends paid per Ordinary Share since launch.

 

 

Issued on behalf of the Board

Maven Capital Partners UK LLP

Secretary

 

4 December 2025

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCTIBMTMTBMBTA
Date   Source Headline
20th May 202610:00 amRNSAdmission of Further Securities to Trading
15th May 202610:05 amRNSIssue of Equity - Dividend Investment Scheme
12th May 20263:35 pmRNSUnaudited NAV - Dividend Investment Scheme
8th May 20267:00 amRNSTransaction in Own Shares
30th Apr 20261:30 pmRNSResult of AGM
30th Apr 202610:54 amRNSAdmission of Further Securities to Trading
29th Apr 202612:28 pmRNSIssue of Equity
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:19 amRNSAdmission of Further Securities to Trading
14th Apr 202611:07 amRNSIssue of Equity
8th Apr 20269:28 amRNSAdmission of Further Securities to Trading
25th Mar 202610:54 amRNSAdmission of Further Securities to Trading
24th Mar 20265:32 pmRNSAnnual Financial Report
24th Mar 202612:11 pmRNSIssue of Equity
17th Mar 20264:36 pmRNSNet Asset Value(s)
27th Feb 20265:01 pmRNSTransaction in Own Shares
27th Feb 20267:00 amRNSUnaudited NAV and Dividend Declaration
18th Feb 20264:52 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:05 amRNSDirector/PDMR Shareholding
17th Feb 202611:02 amRNSDirector/PDMR Shareholding
17th Feb 202611:02 amRNSDirector/PDMR Shareholding
17th Feb 202611:00 amRNSDirector/PDMR Shareholding
17th Feb 202610:55 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:03 amRNSAdmission of Further Securities to Trading
16th Jan 20269:42 amRNSIssue of Equity
14th Jan 20262:35 pmRNSUnaudited NAV - Dividend Investment Scheme
16th Dec 202510:20 amRNSIssue of Equity
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20254:47 pmRNSResult of General Meeting
28th Oct 20254:24 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:08 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:13 pmRNSStatement re Dividend Investment Scheme
23rd Jul 20254:30 pmRNSHalf-year Report
22nd Jul 20254:49 pmRNSTransaction in Own Shares
16th Jul 20257:08 amRNSStatement re Offer for Subscription
10th Jul 20254:46 pmRNSStatement re Unaudited NAV and Interim Dividend
15th May 20253:57 pmRNSTransaction in Own Shares
9th May 20259:54 amRNSDirector/PDMR Shareholding
9th May 20259:51 amRNSIssue of Equity
6th May 202511:53 amRNSIssue of Equity
2nd May 20251:11 pmRNSAudited NAV - Dividend Investment Scheme
1st May 20253:15 pmRNSResult of AGM
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:17 pmRNSIssue of Equity
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.